-
Understanding site variability in a multisite clinical trial of a technology-delivered psychosocial intervention for substance use disorders.
Vaezazizi LM, Campbell ANC, Pavlicova M, Hu M, Nunes EV. Understanding site variability in a multisite clinical trial of a technology-delivered psychosocial intervention for substance use disorders. Journal of Substance Abuse Treatment 2019;105:64-70.
-
A quality framework for emergency department treatment of opioid use disorder.
Samuels EA, D'Onofrio G, Huntley K, Levin S, Schuur JD, Bart G, Hawk K, Tai B, Campbell CI, Venkatesh AK. A quality framework for emergency department treatment of opioid use disorder. Annals of Emergency Medicine 2019;73:237-247.
-
Medication adherence monitoring using smartphone video dosing in an open-label pilot study of monthly naltrexone plus once-daily bupropion for methamphetamine use disorder: Feasibility and acceptability.
Walker NR, Hillhouse M, Perrochet B, Sparenborg S, Mooney L, Ling W. Medication adherence monitoring using smartphone video dosing in an open-label pilot study of monthly naltrexone plus once-daily bupropion for methamphetamine use disorder: Feasibility and acceptability. Journal of Addiction Medicine 2019;13(5):372-378.
-
Blunts versus joints: Cannabis use characteristics and consequences among treatment-seeking adults.
Montgomery L, McClure EA, Tomko RL, Sonne SC, Winhusen TJ, Terry GE, Grossman JT, Gray KM. Blunts versus joints: Cannabis use characteristics and consequences among treatment-seeking adults. Drug and Alcohol Dependence 2019;198:105-111
-
Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.
Evans EA, Zhu Y, Yoo C, Huang D, Hser Y. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. Addiction 2019;114(8):1396-1404.
-
Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: Protocol for a hybrid type iii effectiveness implementation study (Project ED HEALTH).
D'Onofrio G, Edelman EJ, Hawk KF, Pantalon MV, Chawarski MC, Owens PH, Martel SH, VanVeldhuisen PC, Oden NL, Murphy SM, Huntley K, O'Connor PG, Fiellin DA. Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: Protocol for a hybrid type iii effectiveness implementation study (Project ED HEALTH). Implementation Science 2019;14(1):48.
-
Relationship between tobacco use and Health-Related Quality of Life (HRQoL) among clients in substance use disorders treatment.
Campbell BK, Yip D, Le T, Gubner NR, Guydish JR. Relationship between tobacco use and Health-Related Quality of Life (HRQoL) among clients in substance use disorders treatment. Journal of Psychoactive Drugs 2019;51(1):48-57
-
Use of single IRBs for multi-site studies: A case report and commentary from a National Drug Abuse Treatment Clinical Trials Network study.
Nichols C, Kunkel LE, Baker R, Jelstron E, Addis M, Hoffman KA, McCarty D, Korthuis PT. Use of single IRBs for multi-site studies: A case report and commentary from a National Drug Abuse Treatment Clinical Trials Network study. Contemporary Clinical Trials Communications 2019;14:100319.
-
Correlates of opioid abstinence in a 42-month posttreatment naturalistic follow-up study of prescription opioid dependence.
Weiss RD, Griffin ML, Marcovitz DE, Hilton BT, Fitzmaurice GM, McHugh RK, Carroll KM. Correlates of opioid abstinence in a 42-month posttreatment naturalistic follow-up study of prescription opioid dependence. Journal of Clinical Psychiatry 2019;80(2):18m12292.
-
Escalating opioid dose is associated with mortality: A comparison of patients with and without opioid use disorder.
Hser Y, Saxon AJ, Mooney LJ, Miotto K, Zhu Y, Yoo CK, Liang D, Huang D, Bell DS. Escalating opioid dose is associated with mortality: A comparison of patients with and without opioid use disorder. Journal of Addiction Medicine 2019;13(1):41-46